Ticagrelor in the Management of Coronary Artery Disease

References

• Arbustini E , DalBello B, MorbiniPet al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart, 82(3), 269–272 (1999).
   PubMed Web of Science ®Google Scholar
• Ibanez B , VilahurG, BadimonJJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur. Heart J., 8(Suppl. G), G3–G9 (2006).
   Web of Science ®Google Scholar
• Schömig A , NeumannF-J, KastratiAet al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl., 334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Wisman PP , RoestM, AsselbergsFWet al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost., 12(5), 736–747 (2014).
   PubMed Web of Science ®Google Scholar
• Investigators CIUaTPRET . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl., 345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Aradi D . Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am. Heart J., 160(3), 543 (2010).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM , JilmaB. Ticagrelor: from discovery to Phase III clinical trial. Future Cardiol., 6(6), 753–764 (2010).
   PubMedGoogle Scholar
• Dobesh PP , OestreichJH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy, 34(10), 1077–1090 (2014).
   PubMed Web of Science ®Google Scholar
• Husted S , EmanuelssonH, HeptinstallS, SandsetPM, WickensM, PetersG. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J., 27(9), 1038–1047 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP , HustedS, HarringtonRAet al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol., 50(19), 1844–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Bonaca MP , BhattDL, OphuisTOet al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol., 1(4), 425–432 (2016).
   PubMed Web of Science ®Google Scholar
• Bonello L , LaineM, KipsonNet al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J. Am. Coll. Cardiol., 63(9), 872–877 (2014).
   PubMed Web of Science ®Google Scholar
• Gurbel P , BlidenK, AntoninoMet al. The effect of ticagrelor in stable coronary artery disease patients nonresponsive to clopidogrel: the RESPOND study. Circulation, 121(10), 1188–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BlidenKP, HiattBL, O'ConnorCM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107(23), 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BlidenKP, ButlerKet al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. Circulation, 120(25), 2577–2585 (2009).
   PubMed Web of Science ®Google Scholar
• Lindholm D , VarenhorstC, CannonCPet al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur. Heart J., 35(31), 2083–2093 (2014).
   PubMed Web of Science ®Google Scholar
• Wallentin L , BeckerRC, BudajAet al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J., 361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Kohli P , WallentinL, ReyesEet al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation, 127(6), 673–680 (2013).
   PubMed Web of Science ®Google Scholar
• Montalescot G , WiviottSD, BraunwaldEet al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet, 373(9665), 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW , WojdylaDM, CarrollKet al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation, 124(5), 544–554 (2011).
   PubMed Web of Science ®Google Scholar
• Jüni P . Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 364(9450), 2021 (2004).
   PubMed Web of Science ®Google Scholar
• Vranckx P , ValgimigliM, JüniPet al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-la. Lancet, 392(10151), 940–949 (2018).
   PubMed Web of Science ®Google Scholar
• Parker WaE , OrmeRC, HansonJet al. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148–157 (2019).
   PubMed Web of Science ®Google Scholar
• Wilson SJ , NewbyDE, DawsonD, IrvingJ, BerryC. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart, 103(8), 573–580 (2017).
   PubMed Web of Science ®Google Scholar
• Klauss V , SerruysPW, PilgrimTet al. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc. Interv., 4(8), 887–895 (2011).
   PubMed Web of Science ®Google Scholar
• Mehran R , BaberU, SharmaSKet al. Ticagrelor with or without aspirin in high-risk patients after PCI. N. Engl. J. Med., 381(21), 2032–2042 (2019).
   PubMed Web of Science ®Google Scholar
• Hahn J-Y , SongYB, OhJ-Het al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA, 321(24), 2428 (2019).
   PubMed Web of Science ®Google Scholar
• Watanabe H , DomeiT, MorimotoTet al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI. JAMA, 321(24), 2414 (2019).
   PubMed Web of Science ®Google Scholar
• Baber U . Ticagrelor with or without aspirin after PCI: The TWILIGHT Platelet Substudy. J. Am. Coll. Cardiol., 75(6), 578 (2020).
   PubMed Web of Science ®Google Scholar
• Bonaca MP , BhattDL, CohenMet al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl, 372(19), 1791–1800 (2015).
   PubMed Web of Science ®Google Scholar
• Moss AJ , DweckMR, DorisMKet al. Ticagrelor to reduce myocardial injury in patients with high-risk coronary artery plaque. JACC Cardiovasc. Imaging, 13(7), 1549–1560 (2020).
   PubMed Web of Science ®Google Scholar
• Steg PG , BhattDL, SimonTet al. Ticagrelor in patients with stable coronary disease and diabetes. N. Engl. J. Med., 381(14), 1309–1320 (2019).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegPG, MehtaSRet al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a Phase III, placebo-controlled, randomized trial. Lancet, 394(10204), 1169–1180 (2019).
   PubMed Web of Science ®Google Scholar
• Group ASC . Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med., 379(16), 1529–1539 (2018).
   PubMed Web of Science ®Google Scholar
• Motovska Z , HlinomazO, MiklikRet al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Circulation, 134(21), 1603–1612 (2016).
   PubMed Web of Science ®Google Scholar
• Motovska Z , HlinomazO, KalaPet al. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J. Am. Coll. Cardiol., 71(4), 371–381 (2018).
   PubMed Web of Science ®Google Scholar
• Schüpke S , NeumannF-J, MenichelliMet al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N. Engl., 381(16), 1524–1534 (2019).
   PubMed Web of Science ®Google Scholar
• Valgimigli M , BuenoH, ByrneRA, ColletJ-P, CostaFet al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 39, 213–260 (2018).
   PubMed Web of Science ®Google Scholar
• Amsterdam EA , WengerNK, BrindisRG, CaseyDE, GaniatsTGet al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-elevation Acute Coronary Syndromes. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 64, e139–e228 (2014).
   PubMed Web of Science ®Google Scholar
• Knuuti J , WijnsW, SarasteA, CapodannoD, BarbatoEet al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur. Heart J., 41, 407–477 (2020).
   PubMed Web of Science ®Google Scholar
• Lopes RD , HeizerG, AronsonRet al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl, 380(16), 1509–1524 (2019).
   PubMed Web of Science ®Google Scholar
• Oldgren J , StegPG, HohnloserSHet al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur. Heart J., 40(19), 1553–1562 (2019).
   PubMed Web of Science ®Google Scholar
• Vranckx P , ValgimigliM, EckardtLet al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomized, open-label, Phase IIIb trial. Lancet, 394(10206), 1335–1343 (2019).
   PubMed Web of Science ®Google Scholar